Oncology
ASCO 2026: All about DNA damage response, with Luke Piggot
Luke Piggot, a principal scientist at Debiopharm, shares some recent data and news about the company's work in DNA damage repair inhibitors.
Patients
End-of-life choice means little without end-of-life support
A strong end-of-life care system does not wait until the final days to step in.
R&D
Go north: Life sciences excellence shines bright in Sweden
Gothenburg is Sweden's fastest-growing and second largest city region and one of Europe's leading innovation regions.
Sales & Marketing
Is pure play pharma's new pharmakon?
The shift in commercial teams has been happening for some time. This is not new news. I have felt it many times over, like many of us who have worked in the industry for years.
Patients
ASCO 2026: New hope in AL amyloidosis, with Dr Hans Lee
A phase 1/2 trial in AL amyloidosis saw 100% of patients obtaining at least a very good partial response with 90% obtaining a complete response.
Sales & Marketing
Digital
Market Access
Editor's Picks
Editor's Picks
